Objectives: Elevated levels of high sensitivity C-reactive protein (hs-CRP) Is associated with increased incidence of cardiovascular events. We aimed to investigate whether iatrogenic disruption of plaques by percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) would result in a meaningful rise in hs-CRP that could impact shortterm outcome. Methods: From September 2017 to May 2018, we measured hs-CRP in 60 patients divided into 3 groups; group I (20 patients with stable CAD undergoing elective PCI), group II (20 patients with NSTE-ACS undergoing PCI) and group 3 (20 patients with stable and unstable CAD undergoing angiography without PCI). Samples for hs-CRP testing were withdrawn before the procedure, 6 and 24 hours later. Results: In group I, levels increased from 2.4 ± 0.6 at baseline to 8.2 ± 1.7 e2 Abstracts / Atherosclerosis Supplements 33 (2018) e1ee6 mg/L 24 hours later, P < 0.001). In group II, levels increased from 7.7 ± 2.9 at baseline to 12.2 ± 3.5 mg/L 24 hours later, P < 0.001). Group III showed no significant change. The median percent change in group I was significantly higher than both groups II and III (239.09% [117.86 - 566.67] versus 70.47% [- 19.09 - 212.24] and 10.98% [-27.59 - 272.73], P < 0.001). No significant differences in baseline or 24 hours hs-CRP levels were found between those who developed 30-day endpoints and those who did not. Conclusion: Iatrogenic disruption of plaques by PCI in stable CAD resulted in a significant rise of hs-CRP. However, this does not impact short-term outcome.